{
    "organizations": [],
    "uuid": "346a3e1b36b8cc9b2cb0f1254c0caf345b70f3b1",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-soleno-therapeutics-announces-succ/brief-soleno-therapeutics-announces-successful-end-of-phase-ii-meeting-with-fda-for-dccr-in-prader-willi-syndrome-idUSFWN1QA0RY",
    "ord_in_thread": 0,
    "title": "BRIEF-Soleno Therapeutics Announces Successful End-Of-Phase II Meeting With FDA For DCCR In Prader-Willi Syndrome",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 20 (Reuters) - Soleno Therapeutics Inc:\n* SOLENO THERAPEUTICS ANNOUNCES SUCCESSFUL END-OF-PHASE II MEETING WITH FDA FOR DCCR IN PRADER-WILLI SYNDROME\n* SOLENO THERAPEUTICS INC - ‍MINUTES OF MEETING CONFIRMED FDA, CO ALIGNED ON ALL KEY ASPECTS OF CO‘S PLANNED PHASE III CLINICAL TRIAL FOR DCCR Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-20T21:23:00.000+02:00",
    "crawled": "2018-02-21T21:10:21.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "soleno",
        "therapeutic",
        "inc",
        "soleno",
        "therapeutic",
        "announces",
        "successful",
        "ii",
        "meeting",
        "fda",
        "dccr",
        "syndrome",
        "soleno",
        "therapeutic",
        "inc",
        "meeting",
        "confirmed",
        "fda",
        "co",
        "aligned",
        "key",
        "aspect",
        "co",
        "planned",
        "phase",
        "iii",
        "clinical",
        "trial",
        "dccr",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}